captopril has been researched along with allopurinol in 36 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 5 (13.89) | 18.7374 |
| 1990's | 7 (19.44) | 18.2507 |
| 2000's | 11 (30.56) | 29.6817 |
| 2010's | 12 (33.33) | 24.3611 |
| 2020's | 1 (2.78) | 2.80 |
| Authors | Studies |
|---|---|
| Topliss, JG; Yoshida, F | 1 |
| Benz, RD; Contrera, JF; Kruhlak, NL; Matthews, EJ; Weaver, JL | 1 |
| Bellows, DS; Clarke, ID; Diamandis, P; Dirks, PB; Graham, J; Jamieson, LG; Ling, EK; Sacher, AG; Tyers, M; Ward, RJ; Wildenhain, J | 1 |
| Lombardo, F; Obach, RS; Waters, NJ | 1 |
| Ahlin, G; Artursson, P; Bergström, CA; Gustavsson, L; Karlsson, J; Larsson, R; Matsson, P; Norinder, U; Pedersen, JM | 1 |
| González-Díaz, H; Orallo, F; Quezada, E; Santana, L; Uriarte, E; Viña, D; Yáñez, M | 1 |
| Chupka, J; El-Kattan, A; Feng, B; Miller, HR; Obach, RS; Troutman, MD; Varma, MV | 1 |
| Barnes, JC; Bradley, P; Day, NC; Fourches, D; Reed, JZ; Tropsha, A | 1 |
| Chang, G; El-Kattan, A; Miller, HR; Obach, RS; Rotter, C; Steyn, SJ; Troutman, MD; Varma, MV | 1 |
| García-Mera, X; González-Díaz, H; Prado-Prado, FJ | 1 |
| Fisk, L; Greene, N; Naven, RT; Note, RR; Patel, ML; Pelletier, DJ | 1 |
| Ekins, S; Williams, AJ; Xu, JJ | 1 |
| Chen, M; Fang, H; Liu, Z; Shi, Q; Tong, W; Vijay, V | 1 |
| Artursson, P; Haglund, U; Karlgren, M; Kimoto, E; Lai, Y; Norinder, U; Vildhede, A; Wisniewski, JR | 1 |
| Afshari, CA; Chen, Y; Dunn, RT; Hamadeh, HK; Kalanzi, J; Kalyanaraman, N; Morgan, RE; van Staden, CJ | 1 |
| Chen, M; Hu, C; Suzuki, A; Thakkar, S; Tong, W; Yu, K | 1 |
| Jones, LH; Nadanaciva, S; Rana, P; Will, Y | 1 |
| Brodsky, JL; Chiang, A; Chung, WJ; Denny, RA; Goeckeler-Fried, JL; Havasi, V; Hong, JS; Keeton, AB; Mazur, M; Piazza, GA; Plyler, ZE; Rasmussen, L; Rowe, SM; Sorscher, EJ; Weissman, AM; White, EL | 1 |
| Rabkin, SW | 1 |
| Bagchi, D; Das, DK; Prasad, R | 1 |
| Cooper, JD; Egan, TM; Minta, JO; Scrimgeour, KG | 1 |
| Croft, DN; Nunan, TO; O'Doherty, MJ; Pennell, DJ | 1 |
| Burden, AC; Samanta, A | 1 |
| Antonovych, TT | 1 |
| Clapperton, M; Dargie, HJ; Fisher, AC; McMurray, J | 1 |
| Demiryürek, AT; Kane, KA; Wadsworth, RM; Wainwright, CL | 1 |
| Manso, CF; Mira, ML; Queiroz, MJ; Silva, MM | 1 |
| Fujisaki, N; Ikeda, Y; Kuwahara, M; Ohtsuka, Y; Sakemi, T | 1 |
| Bramble, FJ; Morley, R | 1 |
| Metodiewa, D; Winterbourn, CC | 1 |
| Cosic, V; Djordjevic, VB; Jevtovic, T; Kocic, G; Pavlovic, D; Savic, V; Vlahovic, P | 1 |
| Horio, T; Mizuno, K; Okamoto, H | 1 |
| Jeppsson, B; Menger, MD; Riaz, AA; Sato, T; Schramm, R; Thorlacius, H; Wang, Y | 1 |
| Johnson, RJ; Mu, W; Nakagawa, T; Reungjui, S; Roncal, CA; Sánchez-Lozada, LG; Sautin, YY | 1 |
| Ambrosioni, E; Bacchelli, S; Borghi, C; Esposti, DD; Omboni, S; Reggiardo, G | 1 |
| Chen, AD; Chen, Q; Kang, YM; Li, YH; Qiu, Y; Wang, JJ; Ye, C; Zheng, F; Zhu, GQ | 1 |
3 review(s) available for captopril and allopurinol
| Article | Year |
|---|---|
DILIrank: the largest reference drug list ranked by the risk for developing drug-induced liver injury in humans.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Drug Labeling; Humans; Pharmaceutical Preparations; Risk | 2016 |
Drug-induced nephropathies.
Topics: Allopurinol; Aminoglycosides; Analgesics; Anti-Bacterial Agents; Anti-Inflammatory Agents; Captopril; Cephalosporins; Cisplatin; Diuretics; Glomerulonephritis; Gold; Humans; Kidney; Kidney Diseases; Kidney Tubular Necrosis, Acute; Lithium; Nephritis, Interstitial; Penicillamine; Penicillins; Rifampin; Semustine; Sulfonamides; Tetracycline; Trimethadione | 1984 |
Effects of the concomitant administration of xanthine oxidase inhibitors with zofenopril or other ACE-inhibitors in post-myocardial infarction patients: a meta-analysis of individual data of four randomized, double-blind, prospective studies.
Topics: Aged; Angiotensin-Converting Enzyme Inhibitors; Captopril; Double-Blind Method; Enzyme Inhibitors; Female; Humans; Lisinopril; Male; Middle Aged; Myocardial Infarction; Progression-Free Survival; Prospective Studies; Ramipril; Randomized Controlled Trials as Topic; Retrospective Studies; Risk Factors; Time Factors; Treatment Outcome; Xanthine Oxidase | 2018 |
33 other study(ies) available for captopril and allopurinol
| Article | Year |
|---|---|
QSAR model for drug human oral bioavailability.
Topics: Administration, Oral; Biological Availability; Humans; Models, Biological; Models, Molecular; Pharmaceutical Preparations; Pharmacokinetics; Structure-Activity Relationship | 2000 |
Assessment of the health effects of chemicals in humans: II. Construction of an adverse effects database for QSAR modeling.
Topics: Adverse Drug Reaction Reporting Systems; Artificial Intelligence; Computers; Databases, Factual; Drug Prescriptions; Drug-Related Side Effects and Adverse Reactions; Endpoint Determination; Models, Molecular; Quantitative Structure-Activity Relationship; Software; United States; United States Food and Drug Administration | 2004 |
Chemical genetics reveals a complex functional ground state of neural stem cells.
Topics: Animals; Cell Survival; Cells, Cultured; Mice; Molecular Structure; Neoplasms; Neurons; Pharmaceutical Preparations; Sensitivity and Specificity; Stem Cells | 2007 |
Trend analysis of a database of intravenous pharmacokinetic parameters in humans for 670 drug compounds.
Topics: Blood Proteins; Half-Life; Humans; Hydrogen Bonding; Infusions, Intravenous; Pharmacokinetics; Protein Binding | 2008 |
Structural requirements for drug inhibition of the liver specific human organic cation transport protein 1.
Topics: Cell Line; Computer Simulation; Drug Design; Gene Expression Profiling; Humans; Hydrogen Bonding; Liver; Molecular Weight; Organic Cation Transporter 1; Pharmaceutical Preparations; Predictive Value of Tests; Reverse Transcriptase Polymerase Chain Reaction; RNA, Messenger; Structure-Activity Relationship | 2008 |
Quantitative structure-activity relationship and complex network approach to monoamine oxidase A and B inhibitors.
Topics: Computational Biology; Drug Design; Humans; Isoenzymes; Molecular Structure; Monoamine Oxidase; Monoamine Oxidase Inhibitors; Quantitative Structure-Activity Relationship | 2008 |
Physicochemical determinants of human renal clearance.
Topics: Humans; Hydrogen Bonding; Hydrogen-Ion Concentration; Hydrophobic and Hydrophilic Interactions; Kidney; Metabolic Clearance Rate; Molecular Weight | 2009 |
Cheminformatics analysis of assertions mined from literature that describe drug-induced liver injury in different species.
Topics: Animals; Chemical and Drug Induced Liver Injury; Cluster Analysis; Databases, Factual; Humans; MEDLINE; Mice; Models, Chemical; Molecular Conformation; Quantitative Structure-Activity Relationship | 2010 |
Physicochemical space for optimum oral bioavailability: contribution of human intestinal absorption and first-pass elimination.
Topics: Administration, Oral; Biological Availability; Humans; Intestinal Absorption; Pharmaceutical Preparations | 2010 |
Multi-target spectral moment QSAR versus ANN for antiparasitic drugs against different parasite species.
Topics: Antiparasitic Agents; Molecular Structure; Neural Networks, Computer; Parasitic Diseases; Quantitative Structure-Activity Relationship; Species Specificity; Thermodynamics | 2010 |
Developing structure-activity relationships for the prediction of hepatotoxicity.
Topics: Chemical and Drug Induced Liver Injury; Databases, Factual; Humans; Structure-Activity Relationship; Tetracyclines; Thiophenes | 2010 |
A predictive ligand-based Bayesian model for human drug-induced liver injury.
Topics: Bayes Theorem; Chemical and Drug Induced Liver Injury; Humans; Ligands | 2010 |
FDA-approved drug labeling for the study of drug-induced liver injury.
Topics: Animals; Benchmarking; Biomarkers, Pharmacological; Chemical and Drug Induced Liver Injury; Drug Design; Drug Labeling; Drug-Related Side Effects and Adverse Reactions; Humans; Pharmaceutical Preparations; Reproducibility of Results; United States; United States Food and Drug Administration | 2011 |
Classification of inhibitors of hepatic organic anion transporting polypeptides (OATPs): influence of protein expression on drug-drug interactions.
Topics: Atorvastatin; Biological Transport; Drug Interactions; Estradiol; Estrone; HEK293 Cells; Heptanoic Acids; Humans; Hydroxymethylglutaryl-CoA Reductase Inhibitors; In Vitro Techniques; Least-Squares Analysis; Liver; Liver-Specific Organic Anion Transporter 1; Models, Molecular; Multivariate Analysis; Organic Anion Transporters; Organic Anion Transporters, Sodium-Independent; Protein Isoforms; Pyrroles; Solute Carrier Organic Anion Transporter Family Member 1B3; Structure-Activity Relationship; Transfection | 2012 |
A multifactorial approach to hepatobiliary transporter assessment enables improved therapeutic compound development.
Topics: Animals; ATP Binding Cassette Transporter, Subfamily B; ATP Binding Cassette Transporter, Subfamily B, Member 11; ATP-Binding Cassette Transporters; Biological Transport; Chemical and Drug Induced Liver Injury; Cluster Analysis; Drug-Related Side Effects and Adverse Reactions; Humans; Liver; Male; Multidrug Resistance-Associated Proteins; Pharmacokinetics; Rats; Rats, Sprague-Dawley; Recombinant Proteins; Risk Assessment; Risk Factors; Toxicity Tests | 2013 |
Development of a cell viability assay to assess drug metabolite structure-toxicity relationships.
Topics: Adenosine Triphosphate; Benzbromarone; Cell Line; Cell Survival; Chromans; Cytochrome P-450 CYP2C9; Cytochrome P-450 CYP2D6; Cytochrome P-450 CYP3A; Cytochrome P-450 Enzyme System; Humans; Pharmaceutical Preparations; Thiazolidinediones; Troglitazone | 2016 |
Increasing the Endoplasmic Reticulum Pool of the F508del Allele of the Cystic Fibrosis Transmembrane Conductance Regulator Leads to Greater Folding Correction by Small Molecule Therapeutics.
Topics: Alleles; Benzoates; Cells, Cultured; Cystic Fibrosis; Cystic Fibrosis Transmembrane Conductance Regulator; Endoplasmic Reticulum; Furans; Gene Deletion; HEK293 Cells; HeLa Cells; High-Throughput Screening Assays; Humans; Hydroxamic Acids; Microscopy, Fluorescence; Protein Folding; Protein Structure, Tertiary; Pyrazoles; RNA, Messenger; Small Molecule Libraries; Ubiquitination; Vorinostat | 2016 |
Cilazapril and captopril accelerate recovery from hypoxia in myocardial cell aggregates in culture.
Topics: Allopurinol; Angiotensin-Converting Enzyme Inhibitors; Animals; Captopril; Cell Aggregation; Cell Hypoxia; Cells, Cultured; Chick Embryo; Cilazapril; Free Radicals; Heart; Myocardial Contraction; Myocardium; Oxygen; Pyridazines | 1992 |
Direct scavenging of free radicals by captopril, an angiotensin converting enzyme inhibitor.
Topics: Allopurinol; Captopril; Cytochrome c Group; Free Radicals; Hydroxides; Hydroxyl Radical; Hypochlorous Acid; Kinetics; Superoxide Dismutase; Superoxides; Thiourea | 1989 |
Captopril--a potential free radical scavenger: inhibition of PMN NADPH oxidase.
Topics: Captopril; Catalase; Chlorides; Cytochrome c Group; Dithionitrobenzoic Acid; Free Radicals; Humans; Manganese; Manganese Compounds; NADH, NADPH Oxidoreductases; NADP; NADPH Oxidases; Neutrophils; Oxidation-Reduction; Superoxide Dismutase; Superoxides; Tetradecanoylphorbol Acetate; Xanthine; Xanthine Oxidase; Xanthines | 1988 |
Fatal Stevens-Johnson syndrome in a patient on captopril and allopurinol.
Topics: Aged; Allopurinol; Captopril; Drug Synergism; Humans; Kidney Failure, Chronic; Male; Proline; Stevens-Johnson Syndrome | 1984 |
Fever, myalgia, and arthralgia in a patient on captopril and allopurinol.
Topics: Aged; Allopurinol; Captopril; Drug Synergism; Fever; Humans; Joint Diseases; Male; Muscular Diseases; Pain; Proline | 1984 |
Does luminol chemiluminescence detect free radical scavengers?
Topics: Antioxidants; Captopril; Free Radical Scavengers; In Vitro Techniques; Luminescent Measurements; Luminol; Sulfhydryl Compounds; Superoxides; Xanthine Oxidase | 1995 |
Characterization of a method for the detection of drugs with free radical scavenging activity using porcine leukocytes.
Topics: Animals; Antioxidants; Azides; Captopril; Catalase; Drug Evaluation, Preclinical; Free Radical Scavengers; Ionomycin; Leukocytes; Luminescent Measurements; Mannitol; Sodium Azide; Superoxide Dismutase; Swine; Tetradecanoylphorbol Acetate; Xanthine; Xanthine Oxidase; Xanthines | 1994 |
Angiotensin converting enzyme inhibitors as oxygen free radical scavengers.
Topics: Angiotensin-Converting Enzyme Inhibitors; Captopril; Catalase; Chlorides; Deoxyribose; Dimethyl Sulfoxide; Edetic Acid; Enalaprilat; Ferric Compounds; Free Radical Scavengers; Hydroxyl Radical; Hypoxanthine; Hypoxanthines; Lisinopril; Luminescent Measurements; Superoxide Dismutase; Xanthine Oxidase | 1993 |
Drug-related low responsiveness to recombinant human erythropoietin therapy in three patients with end-stage renal disease.
Topics: Aged; Allopurinol; Anemia; Captopril; Drug Interactions; Drug Resistance; Erythropoietin; Female; Humans; Kidney Failure, Chronic; Male; Middle Aged; Piperidines; Recombinant Proteins | 1997 |
Cystitis associated with allopurinol.
Topics: Aged; Allopurinol; Angiotensin-Converting Enzyme Inhibitors; Antimetabolites; Captopril; Cystitis; Humans; Male; Middle Aged | 1997 |
Reactivity of biologically important thiol compounds with superoxide and hydrogen peroxide.
Topics: Acetylcysteine; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cysteamine; Cysteine; Dithiothreitol; Glutathione; Hydrogen Peroxide; Oxygen Consumption; Penicillamine; Reactive Oxygen Species; Sulfhydryl Compounds; Superoxides; Xanthine Oxidase | 1999 |
Does captopril change oxidative stress in puromycin aminonucleoside nephropathy?
Topics: Angiotensin-Converting Enzyme Inhibitors; Animals; Anti-Bacterial Agents; Captopril; Catalase; Glutathione; Glutathione Peroxidase; Kidney; Male; Oxidative Stress; Puromycin; Rats; Rats, Sprague-Dawley; Superoxide Dismutase; Xanthine Oxidase | 2000 |
Inhibitory influences of xanthine oxidase inhibitor and angiotensin I-converting enzyme inhibitor on multinucleated giant cell formation from monocytes by downregulation of adhesion molecules and purinergic receptors.
Topics: Allopurinol; Angiotensin-Converting Enzyme Inhibitors; Captopril; Cell Adhesion Molecules; Cells, Cultured; Down-Regulation; Enzyme Inhibitors; Giant Cells; Humans; Intercellular Adhesion Molecule-1; Monocytes; Receptors, Purinergic; Xanthine Oxidase | 2004 |
Role of angiotensin II in ischemia/reperfusion-induced leukocyte-endothelium interactions in the colon.
Topics: Allopurinol; Angiotensin II; Angiotensin-Converting Enzyme Inhibitors; Animals; Capillaries; Captopril; Cell Adhesion; Chemokines; Chemotaxis, Leukocyte; Colon; Constriction; Disease Models, Animal; Endothelium, Vascular; Enzyme Induction; Gene Expression Regulation; Inflammation; Ischemia; Leukocyte Count; Leukocytes; Losartan; Male; Mesenteric Artery, Superior; Mice; Mice, Inbred C57BL; Mice, Knockout; P-Selectin; Reactive Oxygen Species; Reperfusion Injury; Superoxide Dismutase | 2004 |
Combination of captopril and allopurinol retards fructose-induced metabolic syndrome.
Topics: Allopurinol; Angiotensin-Converting Enzyme Inhibitors; Animal Feed; Animals; Antimetabolites; Body Weight; Captopril; Disease Models, Animal; Drug Synergism; Drug Therapy, Combination; Energy Metabolism; Fructose; Insulin Resistance; Male; Metabolic Syndrome; Rats; Rats, Sprague-Dawley | 2009 |
Angiotensin Type 1 Receptors and Superoxide Anion Production in Hypothalamic Paraventricular Nucleus Contribute to Capsaicin-Induced Excitatory Renal Reflex and Sympathetic Activation.
Topics: 6-Cyano-7-nitroquinoxaline-2,3-dione; Acetophenones; Acetylcysteine; Allopurinol; Angiotensin II; Angiotensin II Type 1 Receptor Blockers; Angiotensin-Converting Enzyme Inhibitors; Animals; Blood Pressure; Capsaicin; Captopril; Ditiocarb; Kidney; Losartan; Male; NADPH Oxidases; Onium Compounds; Paraventricular Hypothalamic Nucleus; Rats; Rats, Sprague-Dawley; Receptor, Angiotensin, Type 1; Reflex; Superoxides | 2020 |